IκBζ is a key driver in the development of psoriasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 43, 2015, Pages E5825-E5833

  Johansen, Claus ^a   Mose, Maike ^a   Ommen, Pernille ^a   Bertelsen, Trine ^a   Vinter, Hanne ^a   Hailfinger, Stephan ^b   Lorscheid, Sebastian ^b   Schulze Osthoff, Klaus ^b,c   Iversen, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cytokines; Inflammation; I B ; Psoriasis

Indexed keywords

DEFB4 PROTEIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; I KAPPA B; I KAPPA B ZETA; IMIQUIMOD; INTERLEUKIN 17; INTERLEUKIN 17C; INTERLEUKIN 19; INTERLEUKIN 23; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NUCLEAR RECEPTOR COACTIVATOR; PROTEIN; PSORIASIN; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DERMATITIS; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PSORIASIS; REGULATORY MECHANISM; SKIN CELL; ANIMAL; CHEMICALLY INDUCED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMINOQUINOLINES; ANIMALS; HUMANS; I-KAPPA B PROTEINS; MICE; PSORIASIS;

EID: 84945583576     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1509971112     Document Type: Article

References (51)

1. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361(5):496-509.
2. Perera GK, Di Meglio P, Nestle FO (2012) Psoriasis. Annu Rev Pathol 7:385-422.
3. Lowes MA, Suárez-Fariñas M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32:227-255.
4. Leonardi CL, et al.; Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349(21):2014-2022.
5. Patel DD, Lee DM, Kolbinger F, Antoni C (2013) Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 72(Suppl 2):ii116-ii123.
6. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 19:163-196.
7. Langley RG, et al.; ERASURE Study Group; FIXTURE Study Group (2014) Secukinumab in plaque psoriasis: Results of two phase 3 trials. N Engl J Med 371(4):326-338.
8. Sanford M, McKeage K (2015) Secukinumab: First global approval. Drugs 75(3):329-338.
9. Mease PJ (2015) Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 27(2):127-133.
10. Chiricozzi A, et al. (2011) Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131(3):677-687.
11. Johansen C, et al. (2005) Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. J Invest Dermatol 124(6):1284-1292.
12. Hoesel B, Schmid JA (2013) The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12:86.
13. Smale ST (2011) Hierarchies of NF-κB target-gene regulation. Nat Immunol 12(8): 689-694.
14. Yamamoto M, et al. (2004) Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature 430(6996):218-222.
15. Cowland JB, Muta T, Borregaard N (2006) IL-1beta-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. J Immunol 176(9):5559-5566.
16. Karlsen JR, Borregaard N, Cowland JB (2010) Induction of neutrophil gelatinaseassociated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta. J Biol Chem 285(19):14088-14100.
17. Trinh DV, Zhu N, Farhang G, Kim BJ, Huxford T (2008) The nuclear I kappaB protein I kappaB zeta specifically binds NF-kappaB p50 homodimers and forms a ternary complex on kappaB DNA. J Mol Biol 379(1):122-135.
18. Okamoto K, et al. (2010) IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. Nature 464(7293):1381-1385.
19. Tsoi LC, et al. (2015) Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat Commun 6:7001.
20. Kao CY, Kim C, Huang F, Wu R (2008) Requirements for two proximal NF-kappaB binding sites and IkappaB-zeta in IL-17A-induced human beta-defensin 2 expression by conducting airway epithelium. J Biol Chem 283(22):15309-15318.
21. Tian S, et al. (2012) Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One 7(9):e44274.
22. Li B, et al. (2014) Transcriptome analysis of psoriasis in a large case-control sample: RNAseq provides insights into disease mechanisms. J Invest Dermatol 134(7):1828-1838.
23. van der Fits L, et al. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182(9):5836-5845.
24. Rizzo HL, et al. (2011) IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 186(3):1495-1502.
25. Yamazaki S, Muta T, Matsuo S, Takeshige K (2005) Stimulus-specific induction of a novel nuclear factor-kappaB regulator, IkappaB-zeta, via Toll/Interleukin-1 receptor is mediated by mRNA stabilization. J Biol Chem 280(2):1678-1687.
26. Johansen C, et al. (2006) Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 176(3):1431-1438.
27. Wilson NJ, et al. (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950-957.
28. Johansen C, et al. (2005) The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 152(1):37-42.
29. Andrés RM, Hald A, Johansen C, Kragballe K, Iversen L (2013) Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. Exp Dermatol 22(5):323-328.
30. Sano S, et al. (2005) Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11(1):43-49.
31. Matsuo S, Yamazaki S, Takeshige K, Muta T (2007) Crucial roles of binding sites for NF-kappaB and C/EBPs in IkappaB-zeta-mediated transcriptional activation. Biochem J 405(3):605-615.
32. Shiina T, et al. (2004) Targeted disruption of MAIL, a nuclear IkappaB protein, leads to severe atopic dermatitis-like disease. J Biol Chem 279(53):55493-55498.
33. Ueta M, et al. (2008) Stat6-independent tissue inflammation occurs selectively on the ocular surface and perioral skin of IkappaBzeta-/- mice. Invest Ophthalmol Vis Sci 49(8):3387-3394.
34. Zheng Y, et al. (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445(7128):648-651.
35. Zaba LC, et al. (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204(13):3183-3194.
36. Wolk K, et al. (2009) IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) 87(5):523-536.
37. Van Belle AB, et al. (2012) IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 188(1):462-469.
38. Boniface K, et al. (2005) IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174(6):3695-3702.
39. Gordon KB, et al. (2014) A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 71(6):1176-1182.
40. Wang CQ, et al. (2014) IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol 134(12):2990-2993.
41. Papp K, et al. (2014) Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 71(6):1183-1190.e3.
42. Johansen C, et al. (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 160(2):319-324.
43. Ramirez-Carrozzi V, et al. (2011) IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 12(12):1159-1166.
44. Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. Nat Rev Immunol 14(9):585-600.
45. Ha HL, et al. (2014) IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc Natl Acad Sci USA 111(33):E3422-E3431.
46. Sønder SU, Paun A, Ha HL, Johnson PF, Siebenlist U (2012) CIKS/Act1-mediated signaling by IL-17 cytokines in context: Implications for how a CIKS gene variant may predispose to psoriasis. J Immunol 188(12):5906-5914.
47. Chang SH, Park H, Dong C (2006) Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 281(47):35603-35607.
48. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G (1996) Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184(4): 1397-1411.
49. Kragballe K, Desjarlais L, Marcelo CL (1985) Increased DNA synthesis of uninvolved psoriatic epidermis is maintained in vitro. Br J Dermatol 112(3):263-270.
50. Hildebrand DG, et al. (2013) IκBζ is a transcriptional key regulator of CCL2/MCP-1. J Immunol 190(9):4812-4820.
51. Ghoreschi K, et al. (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208(11):2291-2303.